OTTAWA – Health Canada’s recent
safety review of oral and injectable fluoroquinolones, a class of antibiotics, found that in rare cases some known side effects may be persistent or disabling. This includes muscular issues such as tendonitis and Achilles tendon rupture, nerve damage such as peripheral neuropathy, and central nervous system issues such as anxiety, dizziness and confusion.
As a result of its safety review, Health Canada is working with manufacturers to include information concerning this rare but serious risk in the product labelling of these drugs.
Fluoroquinolone antibiotics are used to treat several types of infections, including respiratory and urinary tract infections. Reactions can occur hours to weeks after taking a fluoroquinolone.
There are several oral and injectable fluoroquinolones available in Canada, both generic and brand name:
-
ciprofloxacin (Cipro);
-
moxifloxacin (Avelox);
-
levofloxacin;
-
norfloxacin; and
-
ofloxacin.
Health Canada is also working with the Drug Safety and Effectiveness Network and the Canadian Agency for Drugs and Technologies in Health to conduct additional studies to better understand the use of fluoroquinolones in Canada.
If new safety information is identified, Canadians will be updated, as required.
To report a side effect to a health product to Health Canada:
- Call toll-free at 1-866-234-2345
- Visit Health Canada’s Web page on Adverse Reaction Reporting for information on how to report online, by mail or by fax.
Stay connected with Health Canada and receive the latest advisories and product recalls using
social media tools.
Health Canada
(613) 957-2983
(613) 957-2991
1-866 225-0709